Authorized purpose: Synapse 3D Base Tools is medical-imaging software that provides trained medical professionals tools to aid reading, interpreting, reporting, and treatment planning. It accepts DICOM images from imaging devices including CT, MR, CR, US, NM, PT, and XA, and provides viewing, volume rendering, multiplanar reconstruction, fusion, subtraction, segmentation, measurements, annotations, reporting, image management, and modality-specific CT and MR tools. It is not intended for primary diagnostic interpretation of mammography images.
Clinical role
Multimodality image viewing, processing, analysis, measurement, comparison, and reporting under professional review.
Images and patients
Radiological images; modality varies or is not specified in FDA list · Patient anatomy represented in supported DICOM CT, MR, CR, US, NM, PT, and XA images; mammography excluded
Key limitation
Keep in mind: The exact labeling excludes use with or primary diagnostic interpretation of mammography images; supported modality-specific tools and downstream decisions require professional review.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Synapse 3D Base Tools is medical-imaging software that provides trained medical professionals tools to aid reading, interpreting, reporting, and treatment planning. It accepts DICOM images from imaging devices including CT, MR, CR, US, NM, PT, and XA, and provides viewing, volume rendering, multiplanar reconstruction, fusion, subtraction, segmentation, measurements, annotations, reporting, image management, and modality-specific CT and MR tools. It is not intended for primary diagnostic interpretation of mammography images.
Which images or clinical context are in scope?Modality: Radiological images; modality varies or is not specified in FDA list Anatomy or clinical context: Patient anatomy represented in supported DICOM CT, MR, CR, US, NM, PT, and XA images; mammography excluded Input: Supported DICOM CT, MR, PET, SPECT, X-ray, ultrasound, or other labeled medical-image inputs.
Who uses it?Intended users: Trained physicians, radiologists, technologists, and other medical-image professionals.
What does the software produce?Output: Multimodality images, fused views, quantitative results, contours, measurements, and reports for professional review.
What is its most important limitation?Key limitation: The exact labeling excludes use with or primary diagnostic interpretation of mammography images; supported modality-specific tools and downstream decisions require professional review.
Clinical takeaway. Clinical role: Synapse 3D Base Tools is medical-imaging software that provides trained medical professionals tools to aid reading, interpreting, reporting, and treatment planning. It accepts DICOM images from imaging devices including CT, MR, CR, US, NM, PT, and XA, and provides viewing, volume rendering, multiplanar reconstruction, fusion, subtraction, segmentation, measurements, annotations, reporting, image management, and modality-specific CT and MR tools. It is not intended for primary diagnostic interpretation of mammography images.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports non-clinical software verification and validation (system functionality, component, verification, integration, usability, installation/upgrade, labeling and risk-mitigation testing) plus benchmark performance testing on actual clinical images to show that the semi-automatic or automatic segmentation, detection and registration functions achieved the expected accuracy; all tests passed according to the design specifications. The document states the device does not require clinical studies. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Synapse 3D Base Tools is medical-imaging software that provides trained medical professionals tools to aid reading, interpreting, reporting, and treatment planning. It accepts DICOM images from imaging devices including CT, MR, CR, US, NM, PT, and XA, and provides viewing, volume rendering, multiplanar reconstruction, fusion, subtraction, segmentation, measurements, annotations, reporting, image management, and modality-specific CT and MR tools. It is not intended for primary diagnostic interpretation of mammography images.
The exact labeling excludes use with or primary diagnostic interpretation of mammography images; supported modality-specific tools and downstream decisions require professional review.
The exact FDA document reports non-clinical software verification and validation (system functionality, component, verification, integration, usability, installation/upgrade, labeling and risk-mitigation testing) plus benchmark performance testing on actual clinical images to show that the semi-automatic or automatic segmentation, detection and registration functions achieved the expected accuracy; all tests passed according to the design specifications. The document states the device does not require clinical studies. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Testing for verification and validation involved system level functionality test, component testing, verification testing, integration testing, usability testing, installation/upgrade testing, labeling testing, as well as the testing for risk mitigations" … "benchmark performance testing was conducted using actual clinical images to help demonstrate that the semi-automatic or automatic segmentation, detection, and registration functions implemented in Synapse 3D Base Tools achieved the expected accuracy performance.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports non-clinical software verification and validation (system functionality, component, verification, integration, usability, installation/upgrade, labeling and risk-mitigation testing) plus benchmark performance testing on actual clinical images to show that the semi-automatic or automatic segmentation, detection and registration functions achieved the expected accuracy; all tests passed according to the design specifications. The document states the device does not require clinical studies. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Testing for verification and validation involved system level functionality test, component testing, verification testing, integration testing, usability testing, installation/upgrade testing, labeling testing, as well as the testing for risk mitigations" … "benchmark performance testing was conducted using actual clinical images to help demonstrate that the semi-automatic or automatic segmentation, detection, and registration functions implemented in Synapse 3D Base Tools achieved the expected accuracy performance.". Read from the exact FDA decision document on 2026-11-14.
Sensitivity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-04
Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K203103 FDA decision evidence package for Synapse 3D, Synapse 3D Base Tools v6.1
DesignFDA decision evidence and product verification described in the exact submission or PMA decision record.
PopulationPatient anatomy represented in supported DICOM CT, MR, CR, US, NM, PT, and XA images; mammography excluded
Scopeexact submission
Tested versionSynapse 3D, Synapse 3D Base Tools v6.1 configuration described in K203103
IndependenceSponsor or vendor study
K203103
FDA decision material is manufacturer-submitted regulatory evidence. It is not independent clinical validation unless the exact source expressly establishes that distinction; local technical, clinical, privacy, security, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K203103 by exact native submission identifier. This does not exclude product-family, later-version, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-04
Exact-identifier review does not prove absence of all product-family safety signals.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Supported DICOM CT, MR, PET, SPECT, X-ray, ultrasound, or other labeled medical-image inputs.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA package describes Synapse 3D Base Tools as connected through the DICOM standard to medical devices and a PACS, retrieving image data via DICOM-based network communication; new images can be printed on DICOM or Windows printers, and it can be integrated with Fujifilm's Synapse PACS. Interface versions and local compatibility require confirmation.
Scope: Exact FDA submission. Packet wording: "Synapse 3D Base Tools is connected through DICOM standard to medical devices and to a PACS system storing data generated by these medical devices, and it retrieves image data via network communication based on the DICOM standard." … "Images newly created by Synapse 3D Base Tools (V6.1) not only can be displayed on a display, but also can be printed on a hardcopy using a DICOM printer or a Windows printer.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes Synapse 3D Base Tools (V6.1) as application software running on a Windows server/client configuration installed on commercial general-purpose Windows-compatible computers, with retrieved images stored on a local disk it manages. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "The 3D image analysis software Synapse 3D Base Tools (V6.1) is medical application software running on Windows server/client configuration installed on commercial general-purpose Windows-compatible computers." … "The retrieved image data are stored on the local disk managed by Synapse 3D Base Tools (V6.1)". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Multimodality images, fused views, quantitative results, contours, measurements, and reports for professional review.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Multimodality images, fused views, quantitative results, contours, measurements, and reports for professional review.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes Synapse 3D Base Tools (V6.1) as application software running on a Windows server/client configuration installed on commercial general-purpose Windows-compatible computers, with retrieved images stored on a local disk it manages. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The 3D image analysis software Synapse 3D Base Tools (V6.1) is medical application software running on Windows server/client configuration installed on commercial general-purpose Windows-compatible computers." … "The retrieved image data are stored on the local disk managed by Synapse 3D Base Tools (V6.1)". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The exact FDA package describes Synapse 3D Base Tools as connected through the DICOM standard to medical devices and a PACS, retrieving image data via DICOM-based network communication; new images can be printed on DICOM or Windows printers, and it can be integrated with Fujifilm's Synapse PACS. Interface versions and local compatibility require confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Synapse 3D Base Tools is connected through DICOM standard to medical devices and to a PACS system storing data generated by these medical devices, and it retrieves image data via network communication based on the DICOM standard." … "Images newly created by Synapse 3D Base Tools (V6.1) not only can be displayed on a display, but also can be printed on a hardcopy using a DICOM printer or a Windows printer.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Fujifilm Healthcare Americas' Enterprise Imaging security center states that Fujifilm received a SOC 2 Type II report for the previous 12-month period and provides Manufacturer Disclosure Statement for Medical Device Security (MDS2) documentation for Synapse products through its customer portal and a security documentation request form, covering ePHI maintenance/storage/transmission, data backup and removable media, security patch and antivirus installation, remote service access, and ePHI audit logs.
Product family
Checked 2026-10-27
Vendor statement, not an attestation; the SOC 2 report and MDS2 documents were not read (portal/request-gated). Page scope is Fujifilm's Enterprise Imaging (Synapse) line; this entry is a Synapse-named product. Exact-release scope is not established. Not applied to ECHELON (MRI) or Sonosite (ultrasound) entries.
Only trained physicians, radiologists, technologists, and other medical-image professionals should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor K203103 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The exact labeling excludes use with or primary diagnostic interpretation of mammography images; supported modality-specific tools and downstream decisions require professional review.
Exact FDA submission
Checked 2026-09-04
This is buyer-facing monitoring guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.
The exact public deployment topology remains incomplete; establish hosting responsibility, data flow, availability, upgrade, service, and downtime boundaries locally.
exact submission · checked 2026-09-04
FDA-described topology does not establish current hosting contracts, security controls, uptime, or local qualification.
The exact public integration contract remains incomplete; establish and test supported input, output, identity, routing, archive, and downtime behavior locally.
exact submission · checked 2026-09-04
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The exact labeling excludes use with or primary diagnostic interpretation of mammography images; supported modality-specific tools and downstream decisions require professional review.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
exact submission · checked 2026-09-04
No exact-product price or reimbursement determination was promoted.
Monitor K203103 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The exact labeling excludes use with or primary diagnostic interpretation of mammography images; supported modality-specific tools and downstream decisions require professional review.
exact submission · checked 2026-09-04
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda decision material, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared or authorized configuration was found. Obtain a written quote separating license or hardware basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-04 - Exact FDA submission
No exact-product reimbursement determination was promoted in this timeboxed review. Verify payer, site-of-service, coding, coverage, and local payment assumptions independently.
Authorized purpose: VersaViewer supports two-dimensional, three-dimensional, and four-dimensional medical-image series processing and analysis through customizable layouts, multimodality review, and measurements for trained healthcare professionals; it is not for displaying digital mammography for diagnosis.
Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Multi-region anatomy represented in CT, MR, PET, NM, XA, and other supported studies
Authorized purpose: RadioLens v1.0 is a medical diagnostic application for displaying, processing, storing, and transferring DICOM data other than mammography, with filtering, digital manipulation, and quantitative measurements; its optional SpindleX module analyzes potential vertebral displacement in adult cervical or lumbar spine stress X-rays and calculates measurements related to spinal-ligament injury leading to subluxation.
Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Spine, including cervical and lumbar vertebrae; general DICOM images excluding mammography
Authorized purpose: Syngo Dynamics VA40F is a multimodality, vendor-agnostic cardiology image and information system for medical-image management and processing, with post-processing functions for image manipulation and quantification supporting interpretation and analysis for disease detection, diagnosis, and patient management within a healthcare institution's network.
Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Anatomy represented in multimodality cardiology medical images, excluding U.S. digital mammography diagnosis
Authorized purpose: Illumeo is an image-management system for trained professionals, including radiologists. It is a software package used with general-purpose computing hardware to acquire, store, distribute, process, and display images and associated data throughout a clinical environment, including digital image processing, measurement, manipulation, quantification, communication, and storage. It is not to be used for mammography.
Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Images and associated data represented in the clinical environment; mammography excluded
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.